<DOC>
	<DOCNO>NCT01247896</DOCNO>
	<brief_summary>PF-05190457 novel compound propose treatment Type 2 diabetes mellitus . The purpose study evaluate safety tolerability PF-05190457 administration single dose healthy volunteer evaluate plasma drug concentration single dose healthy volunteer .</brief_summary>
	<brief_title>Single Dose Escalation Study PF-05190457 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Healthy male female ( nonchildbearing ) age 18 55 BMI 17.5 30.5 kg/m2 ; total body weight 50 kg ( 110 lb ) 100 kg ( 220 lb ) inclusive Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>